ENDOMETRIAL CANCER: The combination of everolimus, letrozole and metformin delivered OR 28% (all PR) in pretreated patients in this small (n=54) phase II study.


Feb. 17, 2020


Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study

Clinical Cancer Research, Oct. 2019


Purpose: Treatment for patients with recurrent endometrioid endometrial cancer (EEC) are limited as paclitaxel is the only second line chemotherapy with a response rate >13%. Targeting PIK3/mTOR in combination with hormonal therapy has shown promise. The addition of metformin may enhance this response. We conducted a phase II study evaluating everolimus, letrozole, and metformin in advanced/recurrent ECC. Experimental Design: A Simon two-stage design was employed. Women with <2 prior chemotherapy regimens for recurrence were eligible. Pre-treatment biopsy was required, followed by everolimus 10mg PO, letrozole 2.5mg PO, and metformin 500mg PO BID on a 4 week cycle. The primary endpoint was clinical benefit (CB), defined as complete response (CR), partial response (PR), or stable disease (SD) confirmed at 16 weeks. Patients were treated until progression or toxicity. Results: Sixty-two patients were enrolled. Median age was 62 years (40 - 77) with 401 cycles completed, median of 6 cycles (1 - 31). Fifty-four patients were evaluable for response with a CB rate of 50% (27/54). Best overall response (OR) was PR 28% (15/54) and SD 22% (12/54). Thirteen patients received > 12 cycles. Median follow-up was 17.9 months (2 - 47). Median PFS was 5.7 (95% CI 3.0 to 8.1) and OS was 19.6 months (95% CI 14.2 to 26.3). Positive progesterone receptor expression was associated with CB (89.5% versus 27.3%, p=0.001). Conclusions: Everolimus, letrozole and metformin resulted in 50% CB and 28% OR in women with recurrent EC. Progesterone receptor positive tumors may have better response; validation studies are needed.